For years, pharmaceutical contracting followed a familiar rhythm. Rebates anchored negotiations. Volume assumptions shaped access. And once deals were signed, strategies largely held through the year.
That rhythm is breaking.
As contracting season accelerates into February and March, payers are actively testing new models that move beyond traditional rebate structures. Subscription pilots, outcomes-based triggers, and hybrid contracts are no longer theoretical concepts. They’re showing up in real conversations, pilots, and negotiations right now.
The shift isn’t abrupt, but it is unmistakable.
Why Payers Are Pushing for Change
Several forces are converging at once:
- Ongoing pressure to manage total cost of care, not just pharmacy spend
- Greater scrutiny of net price exposure and utilization risk
- Policy-driven uncertainty influencing long-term pricing assumptions
- A growing expectation that manufacturers share risk, not just discount price
Flat rebates alone don’t always solve these challenges. For many payers, they’ve become a starting point — not the endgame.
What Payers Are Testing on the Ground
While approaches vary by market and therapy area, several patterns are emerging:
Subscription-style arrangements
Often referred to as “Netflix models,” these contracts cap spend in exchange for broader access. Initially tested in limited settings, payers are now exploring where this model could apply beyond its early use cases.
Outcomes-based triggers
Rather than tying payment solely to utilization, some contracts now include performance conditions, such as persistence, response durability, or downstream utilization impact. These arrangements remain selective, but interest is growing.
Hybrid contracts
Increasingly, payers are blending traditional rebates with outcomes components, utilization caps, or scenario-based adjustments. These models offer flexibility while preserving financial guardrails.
What’s notable isn’t that every payer is adopting these models — it’s that many are actively experimenting with them.
What This Means for Manufacturers Right Now
As negotiations intensify, manufacturers face a different set of preparation requirements than in years past.
Contracting readiness now depends on:
- The ability to model multiple contract structures side by side
- A clear understanding of downside and upside exposure under different scenarios
- Evidence that can support performance-based conditions
- Cross-functional alignment between Access, HEOR, Medical, and Commercial teams
Teams that rely on a single contracting assumption risk being caught flat-footed when payers introduce alternatives mid-negotiation.
Why Flexibility Matters This Contracting Cycle
This contracting season isn’t about abandoning rebates altogether. It’s about navigating choice.
Payers are presenting more options, more conditions, and more variability. Manufacturers that can pressure-test contract structures, understand tradeoffs, and respond quickly will be better positioned to protect access and margin simultaneously.
This is where decision-grade modeling and scenario testing, the kind supported by platforms like Elasticity™ and Contracting ROI at eMAX Health Systems, becomes essential. Not to dictate outcomes, but to help teams enter negotiations prepared for the range of possibilities on the table.
The contracting shift isn’t coming. It’s already underway.
The question for manufacturers isn’t whether alternative models will appear, it’s whether their teams are ready to evaluate, respond to, and negotiate them with confidence.